<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189016</url>
  </required_header>
  <id_info>
    <org_study_id>LC.002</org_study_id>
    <nct_id>NCT04189016</nct_id>
  </id_info>
  <brief_title>Nasal Muco-ciliary Clearance Study With and Without Saltinhalation</brief_title>
  <official_title>Nasal Muco-ciliary Clearance Study With and Without Saltinhalation Via a Salt Particle Inhaler at COPD, Asthma and Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liita Care ApS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liita Care ApS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating nasal muco-ciliary clearance by scintigraphy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The velocity and the retention of the nasal muco-ciliary clearance is going to be
      investigated with a salt particle inhaler and a placebo by the method nasal scintigraphy.

      The hypotheses is that nasal inhalation of salt particles enhance the nasal mucociliary
      clearance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal Mucociliary Clearance</measure>
    <time_frame>At study day 1 and 2</time_frame>
    <description>Change in nasal mucociliary clearance velocity (mm/min) from placebo to salt inhalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nasal Mucociliary Clearance</measure>
    <time_frame>At study day 1 and 2</time_frame>
    <description>Change in nasal mucociliary clearance retention (%) from placebo to salt inhalation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>At the beginning and the end of study day 1 and 2</time_frame>
    <description>Change in FEV! from placebo to saltinhalation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saccharin test</measure>
    <time_frame>At study day 1 and 2</time_frame>
    <description>Change in time for saccharin transport</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Obstructive Airway Diseases</condition>
  <arm_group>
    <arm_group_label>Salt particle inhaler with content</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants inhaling from a salt particle inhaler with content</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salt particle inhaler without content</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants inhaling from a salt particle inhaler without content</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Inhalation from a salt particle inhaler with or without content</intervention_name>
    <description>Inhalation from inhaler with (active) or without (placebo) content</description>
    <arm_group_label>Salt particle inhaler with content</arm_group_label>
    <arm_group_label>Salt particle inhaler without content</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD patients (all severities in chronic, stable condition)

          -  Asthma patients (in stable condition without acute asthma symptoms)

          -  Healthy people (no chronic nasal, upper or lower respiratory diseases)

        Exclusion Criteria:

          -  Age under 18 years

          -  Upper respiratory tract infection / cold within the last 3 weeks and at least 3 weeks
             must pass from the person has become well to the examination

          -  Allergic / non-allergic rhinitis (hay fever)

          -  Chronic sinusitis

          -  Acute respiratory tract infection in antibiotic therapy

          -  Applied salt inhalation within the past month

          -  Pregnant or breastfeeding women

          -  Nuclear medical examination within the past month

          -  Cannot taste saccharin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zainab Saraj, Cand.Pharm.</last_name>
    <phone>0045 22268865</phone>
    <email>zs@liitacare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet, Clin nuclear and physiolog dept.</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jann Mortensen, MD Professor</last_name>
      <phone>+45 3545 4011</phone>
      <email>Jann.Mortensen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

